Photo of Stefanie Colella-Walsh

Stefanie Colella-Walsh is a Shareholder and member of Stark & Stark’s Litigation, Insurance Coverage & Liability, Intellectual Property and Mass Torts Groups where she concentrates her practice in complex litigation with a focus in mass tort and pharmaceutical litigation. She is currently involved in representing numerous plaintiffs in federal and state environmental and pharmaceutical mass tort cases, as well as state and federal class action litigations based upon commercial, employment, civil rights, investments/securities and consumer fraud claims. Ms. Colella-Walsh frequently writes about timely legal and legislative developments impacting plaintiffs in mass tort and product liability actions for Stark & Stark’s Mass Tort Law Blog.

In the face of mounting nationwide lawsuits and continuing alarming testing data, the United States Food and Drug Administration (FDA) has finally announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. As a result of this immediate market withdrawal request, ranitidine products (commonly known by the brand name Zantac) will not be available for new or existing prescriptions or OTC use in the U.S.

The FDA is also advising consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, and seek other drugs approved for the same or similar uses as ranitidine that do not carry the same cancer risks.


Continue Reading FDA Zantac Recall: Too Little, Too Late

You have seen a lot of commercials and have probably been searching the internet for some straightforward explanations about Paragard. Here is a simple guide to Paragard lawsuits and settlements in four easy steps:

  • Step 1: Get Your Medical Records Confirming Your IUD Implant.
  • Step 2: Identify Your Paragard IUD Implant.
  • Step 3: Identify Your Related Injury.
  • Step 4: Contact a Paragard Attorney.


Continue Reading A Simple Guide to Paragard Lawsuits and Settlements

So, what is my defective hernia mesh case worth?

It is a very simple question, but you have done quite a bit of research and consulted with supposed experts – and no one can give you a straight answer. The answer is that no one knows specifically what your case is worth right now, that is why there are ongoing nationwide litigations. But before you go back to your Google search, while no one can tell you specifically what your case is worth, we can tell you what attorneys consider when they estimate the potential value of hernia mesh cases.

Here is what you need to consider:

  1. What were the settlement values in similar litigations?
  2. What are the strengths and weaknesses of your individual case?
  3. What can you expect to walk away with?

Helpful hint: If someone does tell you that they know exactly what your hernia mesh case is worth – at best they have no idea what they are talking about; and at worst they are an infomercial trying to sell you something. The same holds true for anyone guaranteeing a favorable outcome. This is litigation and there is always a chance that plaintiffs in litigation lose, making their cases worth nothing.


Continue Reading A Guide to Figuring Out What Your Defective Hernia Mesh Case is Worth

How Do I Know If I Have a Zantac Cancer Claim?

You have already done quite a bit of internet research and likely found that getting to the answer can be a little more complicated than it sounds. “Zantac” is just the brand name of a popular heartburn drug called ranitidine (kind of like Xerox is just the popular brand name of a copy machine). So we will just use the name Zantac to loosely refer to all ranitidine products. Zantac can be prescribed by a doctor or purchased over-the-counter, for different digestive issues. Zantac is produced by a bunch of drug companies you know (Pfizer, GlaxoSmithKline, Sanofi, Boehringer, etc.) and a bunch of generic drug manufacturers that you have probably never heard of. You have also likely been told by now that generic drug companies are generally immune to lawsuits (yes and no – but you likely will have to prove that you were not taking generic Zantac only). In addition, you may have been taking combinations of different types of Zantac over several years, and you obviously did not save all of your Zantac receipts. All of this starts to seem complicated, but you have to break it down into more manageable parts.


Continue Reading A Simple Guide to Zantac Cancer Lawsuits and Settlements

The primary Bard Hernia Mesh state litigation, pending in Rhode Island state court under Judge Gibney, is now set to begin its first bellwether trials that will focus on claims involving the Ventralex patch product, and proceed to trials involving the Composix E/X product. Not to be outdone, and though only designated in August 2018, the Bard Hernia Mesh Multidistrict Litigation (“MDL”) in the United States District Court for the Southern District of Ohio under Judge Sargus, is also steaming along. Plaintiffs and Defendants have narrowed down the initial bellwether pool to six cases – three cases chosen by each side. On January 13, 2020, the parties will submit briefing detailing which cases each party believes should go to trial. Based on that briefing, on January 24, 2020, the Court will select three of those cases for the first bellwether trials. After remaining case specific discovery and motion practice, those cases will go to trial on May 11, 2020; July 13, 2020; and September 14, 2020.

Continue Reading Bard Hernia Mesh Cases Leading the Charge to Settlements in Hernia Mesh Litigations

What is Zantac (ranitidine)?

You have seen a lot of commercials and have probably been searching the internet for some straightforward explanations about Zantac Cancer Lawsuits and Settlements.

Very simply, Zantac is the brand name of a common heartburn medication called ranitidine. Zantac (ranitidine) is a type of drug known as an H2 blocker, or H2 antagonist, which decreases stomach acid by blocking histamine receptors in the stomach. It can be used to treat peptic ulcers, gastroesophageal reflux disease, and related conditions.


Continue Reading What is the Deal With Zantac Cancer Lawsuits and Settlements?

The potential issues with Zantac just became a little more complicated. Zantac is the brand name of a common heartburn medication called ranitidine. As we have reported, there have been multiple, and ongoing, recalls of ranitidine after testing of lots of the drug showed unacceptable levels of the probable human carcinogen N-nitrosodimethylamine (NDMA).

Continue Reading Zantac and Cancer: the Plot Thickens

On October 24, 2019, the United States Food and Drug Administration (“FDA”) issued a draft guidance addressing textured breast implants that have been linked to breast implant-associated anaplastic large cell lymphoma (“BIA-ALCL”).”

Continue Reading FDA Recommends New Warnings for Breast Implants Alleged to Cause Cancer

On October 3, 2019, Plaintiffs in several pending class actions made a motion before the Judicial Panel on Multidistrict Litigation, to centralize related Allergan Biocell textured breast implants lawsuits in a Multidistrict Litigation. The Judicial Panel on Multidistrict Litigation (“JPML”) is a panel of appellate and district court judges that determine whether or not to create an MDL. A Multidistrict Litigation (“MDL”) is a procedure whereby qualifying cases filed in federal district courts throughout the nation are consolidated in one federal district court, before a single judge. If an MDL is created, the JPML then selects the district court and assigns a judge to preside over the litigation.

Continue Reading Allergan Breast Implants Alleged to Cause Cancer

We have already written at length about the nationwide litigation alleging contamination of Valsartan, Losartan, and Irbesartan, with carcinogenic substances. Basically, the claims are that generic versions of those drugs were being made overseas using poor manufacturing processes that caused the drugs to be tainted with impurities.

That contamination included the probable human carcinogen N-nitrosodimethylamine (NDMA), prompting mass recalls by the Federal Drug Administration (FDA). Those pending lawsuits point out that NDMA is the substance actually used in research facilities to induce cancer in lab rats. Accordingly, individual claims in those cases allege serious injuries such as liver damage and various cancers (including liver, kidney, colorectal, and gastric cancers).


Continue Reading First Valsartan, Now Zantac: Cancer Causing Impurities in Foreign-Made Drugs